Abstract |
Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops.
|
Authors | Akiko Yamashita, Nobuhiro Hidaka, Ryo Yamamoto, Soichiro Nakayama, Jun Sasahara, Keisuke Ishii, Nobuaki Mitsuda |
Journal | Journal of clinical ultrasound : JCU
(J Clin Ultrasound)
Vol. 43
Issue 7
Pg. 451-7
(Sep 2015)
ISSN: 1097-0096 [Electronic] United States |
PMID | 25042751
(Publication Type: Case Reports, Journal Article, Review)
|
Copyright | © 2014 Wiley Periodicals, Inc. |
Chemical References |
- Glucocorticoids
- Betamethasone
|
Topics |
- Adult
- Betamethasone
(therapeutic use)
- Cystic Adenomatoid Malformation of Lung, Congenital
(diagnostic imaging, drug therapy)
- Female
- Fetal Diseases
(diagnostic imaging, drug therapy)
- Glucocorticoids
(therapeutic use)
- Humans
- Pregnancy
- Treatment Outcome
- Ultrasonography, Prenatal
|